Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy [Figure presented]

European Urology

Volumn 72, Issue 4, 2017, Pages 544-554

  Seiler, Roland ^a,b   Ashab, Hussam Al Deen ^c   Erho, Nicholas ^c   van Rhijn, Bas W G ^d   Winters, Brian ^e   Douglas, James ^f   Van Kessel, Kim E ^g   Fransen van de Putte, Elisabeth E ^d   Sommerlad, Matthew ^f   Wang, Natalie Q ^c   Choeurng, Voleak ^c   Gibb, Ewan A ^c   Palmer Aronsten, Beatrix ^c   Lam, Lucia L ^c   Buerki, Christine ^c   Davicioni, Elai ^c   Sjödahl, Gottfrid ^h   Kardos, Jordan ⁱ   Hoadley, Katherine A ⁱ   Lerner, Seth P ^j   McConkey, David J ^k   Choi, Woonyoung ^k   Kim, William Y ⁱ   Kiss, Bernhard ^b   Thalmann, George N ^b   Todenhöfer, Tilman ^a   Crabb, Simon J ^f   North, Scott ^l   Zwarthoff, Ellen C ^g   Boormans, Joost L ^g   Wright, Jonathan ^e   Dall'Era, Marc ^m   van der Heijden, Michiel S ^d   Black, Peter C ^a   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BERN   (Switzerland)

^c GenomeDx Biosciences Inc   (Canada)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h LUND UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l UNIVERSITY OF ALBERTA   (Canada)

^m UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Bladder cancer; Molecular subtypes; Neoadjuvant chemotherapy; Response prediction

Indexed keywords

CISPLATIN; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLASSIFIER; CLINICAL OUTCOME; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE EXPRESSION; GENOMIC SUBTYPING CLASSIFIER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE INVASIVE BLADDER CANCER; NEOADJUVANT CHEMOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TRANSCRIPTOMICS; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; AREA UNDER THE CURVE; BLADDER TUMOR; COMPARATIVE STUDY; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR INVASION; WHOLE EXOME SEQUENCING;

AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TIME FACTORS; TRANSCRIPTOME; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; WHOLE EXOME SEQUENCING;

EID: 85017144247     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.03.030     Document Type: Article

References (20)

1. Bajorin, D.F., Herr, H.W., Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift?. J Clin Oncol. 29 (2011), 2135–2137.
2. Grossman, H.B., Natale, R.B., Tangen, C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 (2003), 859–866.
3. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29 (2011), 2171–2177.
4. Zargar, H., Espiritu, P.N., Fairey, A.S., et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 67 (2015), 241–249.
5. Groenendijk, F.H., de Jong, J., Fransen van de Putte, E.E., et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 69 (2016), 384–388.
6. Liu, D., Plimack, E.R., Hoffman-Censits, J., et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2 (2016), 1094–1096.
7. Plimack, E.R., Dunbrack, R.L., Brennan, T.A., et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 68 (2015), 959–967.
8. Van Allen, E.M., Mouw, K.W., Kim, P., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4 (2014), 1140–1153.
9. Biton, A., Bernard-Pierrot, I., Lou, Y., et al. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. Cell Rep 9 (2014), 1235–1245.
10. Cancer Genome Atlas Research Network, Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 (2014), 315–322.
11. Choi, W., Porten, S., Kim, S., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25 (2014), 152–165.
12. Damrauer, J.S., Hoadley, K.A., Chism, D.D., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111 (2014), 3110–3115.
13. Sjodahl, G., Lauss, M., Lovgren, K., et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18 (2012), 3377–3386.
14. Volkmer, J.P., Sahoo, D., Chin, R.K., et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A 109 (2012), 2078–2083.
15. Kardos, J., Chai, S., Mose, L.E., et al. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight, 1, 2016, e85902.
16. Erho, N., Crisan, A., Vergara, I.A., et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One, 8, 2013, e66855.
17. Piccolo, S.R., Sun, Y., Campbell, J.D., Lenburg, M.E., Bild, A.H., Johnson, W.E., A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics 100 (2012), 337–344.
18. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
19. Sharma, P., Retz, M., Siefker-Radtke, A., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18 (2017), 312–322.
20. von Minckwitz, G., Untch, M., Blohmer, J.U., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30 (2012), 1796–1804.